Source: Eur Respir J, 56 (6) 2003508; 10.1183/13993003.03508-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Yuben P. Moodley, Christopher Zappala, Chantalia Tedja, Britt Clynick, Dino B.A. Tan, Eugene Haydn Walters. Comment on “The natural history of progressive fibrosing interstitial lung diseases”. Eur Respir J, 56 (6) 2003508; 10.1183/13993003.03508-2020

Member's Comments

No comment yet.

Related content which might interest you: Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases” Source: Eur Respir J, 56 (6) 2003967; 10.1183/13993003.03967-2020 Year: 2020 The natural history of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020 Year: 2020 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 Clinicoradiological features of chronic fibrosing interstitial pneumonia with smoking history Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Source: Eur Respir Rev 2012 21: 355-361 Year: 2012 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Genetics of fibrosing lung diseases Source: Eur Respir J 2005; 25: 915-927 Year: 2005 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Source: Eur Respir J 2011; 38: 384-391 Year: 2011 Rare interstitial lung diseases of environmental origin Source: Eur Respir Mon 2011; 54: 301-316 Year: 2011 The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018 Year: 2018 Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD) Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Smoking-related interstitial lung diseases: a concise review Source: Eur Respir J 2001; 17: 122-132 Year: 2001 Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia Source: International Congress 2016 – Connective tissue disorders Year: 2016 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015